Scientist Immuno-Oncology Solid Tumor

Scientist Immuno-Oncology Solid Tumor

Cellectis Inc.

New York, NY, United States

<!—
/* Font Definitions /
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:Times;
panose-1:2 0 5 0 0 0 0 0 0 0;
mso-font-charset:0;
mso-generic-font-family:roman;
mso-font-pitch:variable;
mso-font-signature:3 0 0 0 1 0;}
@font-face
{font-family:“Cambria Math”;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:roman;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073786111 1 0 415 0;}
@font-face
{font-family:“MS Mincho”;
panose-1:2 2 6 9 4 2 5 8 3 4;
mso-font-charset:128;
mso-generic-font-family:roman;
mso-font-pitch:fixed;
mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
/
Style Definitions /
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:0cm;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:“Calibri”,sans-serif;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:“Times New Roman”;
mso-fareast-language:EN-US;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:“Times New Roman”,serif;
mso-fareast-font-family:“Times New Roman”;}
span.hiddentext0
{mso-style-name:hiddentext_0;
mso-style-unhide:no;}
span.Hyperlink1
{mso-style-name:“Hyperlink\.1”;
mso-style-unhide:no;
mso-style-parent:"";
mso-ansi-font-size:11.0pt;
mso-bidi-font-size:11.0pt;
font-family:“Arial”,sans-serif;
mso-ascii-font-family:Arial;
mso-fareast-font-family:Arial;
mso-hansi-font-family:Arial;
mso-bidi-font-family:Arial;
color:black;
mso-ansi-language:EN-US;
text-underline:black;}
p.p1, li.p1, div.p1
{mso-style-name:p1;
mso-style-unhide:no;
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:8.5pt;
font-family:“Helvetica”,sans-serif;
mso-fareast-font-family:“MS Mincho”;
mso-bidi-font-family:“Times New Roman”;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-size:10.0pt;
mso-ansi-font-size:10.0pt;
mso-bidi-font-size:10.0pt;
font-family:“Calibri”,sans-serif;
mso-ascii-font-family:Calibri;
mso-fareast-font-family:Calibri;
mso-hansi-font-family:Calibri;}
@page WordSection1
{size:595.3pt 841.9pt;
margin:70.85pt 70.85pt 22.65pt 63.75pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
/
List Definitions */
@list l0
{mso-list-id:1053231182;
mso-list-template-ids:-1648869350;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1144270795;
mso-list-template-ids:-2027003782;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
—>

Cellectis is a clinical-stage
biopharmaceutical company focused on developing a new generation of cancer
immunotherapies based on gene-edited allogeneic T-cells (UCART). By
capitalizing on its 19 years of expertise in gene editing – built on its
flagship TALEN® technology and pioneering electroporation system PulseAgile –
Cellectis uses the power of the immune system to target and eradicate cancer
cells.

Using its
life-science-focused, pioneering genome engineering technologies, Cellectis’
goal is to create innovative products in multiple fields and with various
target markets. Cellectis is listed on the Nasdaq (ticker: CLLS) and on
Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We
do it. TALEN® is a registered trademark owned by Cellectis.

 

Job summary

 

We are seeking
a highly motivated individual to join the Immuno-Oncology team as a Scientist.
The candidate will develop innovative therapeutic approaches for adoptive
immunotherapy of solid tumors. The ideal candidate is an enthusiastic
immunologist with strong interest in solid tumor biology, excellent skills in
T-cell biology and murine models.  He/she has an outstanding track record
and excellent communication skills. We are looking for self-driven and dynamic
candidates that thrive being part of a team and can efficiently work as
individuals. The successful candidate will be part of a fast-moving,
goal-oriented environment aiming to make a change in cancer immunotherapy.

 

The successful candidate will:

 

  • Work as part of the research team at Cellectis to
    develop next generation CAR-T cell therapies to address solid tumor
    indications.
  • Contribute both intellectually and experimentally
    to internal projects from inception through preclinical and clinical
    development.
  • Independently design, analyze and execute in
    vitro
    and in vivo experiments.
  • Communicate results clearly and concisely at
    internal and external meetings to contribute to daily advancement and
    strategic decisions.
  • Publish results in peer reviewed journals to
    foster the company’s visibility.
  • Foster cross-functional collaborations
    both internally and externally
    .
  • Proactively propose and assess innovative cell
    engineering solutions to develop the company’s intellectual property.
  • Keep accurate record of experiments and results.

 

Qualifications and Education Requirements:

 

  • Ph.D. in immunology, oncology or related fields
  • Strong background in solid tumor immuno-oncology,
    human T-cell biology and a good knowledge in cell engineering
    technologies.
  • Extensive hands-on experience in xenogeneic
    murine tumor models (including PDX)
  • Solid expertise in immunology assays including
    immune cell isolation, multicolor flow cytometry, immune cell and cytokine
    profiling assays using conventional and next-generation analytical methods
  • Experience
    in primary cell culture
  • Experience cancer vaccine is a plus.
  • Candidate must have excellent written/oral
    communication skills and strong track record of scientific publications
  • Comfortable in a fast-paced environment and able
    to multi-task and adjust workload based upon changing priorities
  • Be a team player and efficiently work as an
    individual

 

Contact 

 

Applicants should send their CV and motivation letter
to:

CLI_SIO_2019-02@cellectis.com

Favorite

Apply with CV and Cover Letter

Fields with a * are mandatory
Must be a .doc, .docx, or .pdf file and no larger than 1MBMust be a .doc, .docx, or .pdf file and no larger than 1MB
Position

Scientist Immuno-Oncology Solid Tumor